This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Jul;15(7):385.

doi: 10.1038/s41584-019-0252-4.

Engineered fusion protein disrupts CD40 signalling

Affiliations

PMID: 31168100
DOI: 10.1038/s41584-019-0252-4

Comment

Engineered fusion protein disrupts CD40 signalling

Sarah Onuora. Nat Rev Rheumatol. 2019 Jul.

. 2019 Jul;15(7):385.

doi: 10.1038/s41584-019-0252-4.

Author

Affiliation

¹ Nature Reviews Rheumatology, . nrrheum@nature.com.

PMID: 31168100
DOI: 10.1038/s41584-019-0252-4

No abstract available

PubMed Disclaimer

Comment on

A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.
Karnell JL, Albulescu M, Drabic S, Wang L, Moate R, Baca M, Oganesyan V, Gunsior M, Thisted T, Yan L, Li J, Xiong X, Eck SC, de Los Reyes M, Yusuf I, Streicher K, Müller-Ladner U, Howe D, Ettinger R, Herbst R, Drappa J. Karnell JL, et al. Sci Transl Med. 2019 Apr 24;11(489):eaar6584. doi: 10.1126/scitranslmed.aar6584. Sci Transl Med. 2019. PMID: 31019027

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database
Research Materials
- NCI CPTC Antibody Characterization Program